171 related articles for article (PubMed ID: 23348532)
1. The utility of NT-proBNP and various echocardiographic methods in the determination of doxorubicin induced subclinical late cardiotoxicity.
Yildirim A; Tunaoglu FS; Kambur K; Pinarli FG
Kardiol Pol; 2013; 71(1):40-6. PubMed ID: 23348532
[TBL] [Abstract][Full Text] [Related]
2. NT-proBNP as early marker of subclinical late cardiotoxicity after doxorubicin therapy and mediastinal irradiation in childhood cancer survivors.
Zidan A; Sherief LM; El-sheikh A; Saleh SH; Shahbah DA; Kamal NM; Sherbiny HS; Ahmad H
Dis Markers; 2015; 2015():513219. PubMed ID: 25960594
[TBL] [Abstract][Full Text] [Related]
3. Plasma concentrations of NT-pro-BNP and cardiac troponin-I in relation to doxorubicin-induced cardiomyopathy and cardiac function in childhood malignancy.
Soker M; Kervancioglu M
Saudi Med J; 2005 Aug; 26(8):1197-202. PubMed ID: 16127512
[TBL] [Abstract][Full Text] [Related]
4. Predictive value of B-type natriuretic peptides in detecting latent left ventricular diastolic dysfunction in beta-thalassemia major.
Kremastinos DT; Hamodraka E; Parissis J; Tsiapras D; Dima K; Maisel A
Am Heart J; 2010 Jan; 159(1):68-74. PubMed ID: 20102869
[TBL] [Abstract][Full Text] [Related]
5. Use of N-terminal pro-brain natriuretic peptide to assess left ventricular function after adjuvant doxorubicin therapy in early breast cancer patients: a prospective series.
Cil T; Kaplan AM; Altintas A; Akin AM; Alan S; Isikdogan A
Clin Drug Investig; 2009; 29(2):131-7. PubMed ID: 19133708
[TBL] [Abstract][Full Text] [Related]
6. Use of cardiac markers for monitoring of doxorubixin-induced cardiotoxicity in children with cancer.
Pongprot Y; Sittiwangkul R; Charoenkwan P; Silvilairat S
J Pediatr Hematol Oncol; 2012 Nov; 34(8):589-95. PubMed ID: 23018571
[TBL] [Abstract][Full Text] [Related]
7. The use of biochemical markers in cardiotoxicity monitoring in patients treated for leukemia.
Horácek JM; Pudil R; Tichý M; Jebavý L; Strasová A; Praus R; Zák P; Malý J
Neoplasma; 2005; 52(5):430-4. PubMed ID: 16151589
[TBL] [Abstract][Full Text] [Related]
8. [Comparison of plasmatic levels of B-natriuretic peptide with echocardiographic indicators of left ventricle function after doxorubicin therapy].
Elbl L; Vásová I; Navrátil M; Vorlícek J; Malásková L; Spinar J
Vnitr Lek; 2006 Jun; 52(6):563-70. PubMed ID: 16871759
[TBL] [Abstract][Full Text] [Related]
9. Correlation of plasma N-terminal pro-brain natriuretic peptide levels with left ventricle mass in children treated with anthracyclines.
Germanakis I; Kalmanti M; Parthenakis F; Nikitovic D; Stiakaki E; Patrianakos A; Vardas PE
Int J Cardiol; 2006 Apr; 108(2):212-5. PubMed ID: 16290101
[TBL] [Abstract][Full Text] [Related]
10. The N-terminal pro-brain natriuretic peptide as a marker of mitoxantrone-induced cardiotoxicity in multiple sclerosis patients.
Podlecka-Piętowska A; Kochanowski J; Zakrzewska-Pniewska B; Opolski G; Kwieciński H; Kamińska AM
Neurol Neurochir Pol; 2014; 48(2):111-5. PubMed ID: 24821636
[TBL] [Abstract][Full Text] [Related]
11. Echocardiographic evaluation of systolic and diastolic function: a preoperative study of correlation with serum NT-proBNP.
Frederiksen CA; Juhl-Olsen P; Jakobsen CJ; Sloth E
J Cardiothorac Vasc Anesth; 2012 Apr; 26(2):197-203. PubMed ID: 21955828
[TBL] [Abstract][Full Text] [Related]
12. Plasma amino-terminal pro-B-type natriuretic peptide quantification in hypertrophic cardiomyopathy.
Arteaga E; Araujo AQ; Buck P; Ianni BM; Rabello R; Mady C
Am Heart J; 2005 Dec; 150(6):1228-32. PubMed ID: 16338263
[TBL] [Abstract][Full Text] [Related]
13. N-terminal-proB-type natriuretic peptide as a marker for acute anthracycline cardiotoxicity in children.
Ekstein S; Nir A; Rein AJ; Perles Z; Bar-Oz B; Salpeter L; Algur N; Weintraub M
J Pediatr Hematol Oncol; 2007 Jul; 29(7):440-4. PubMed ID: 17609620
[TBL] [Abstract][Full Text] [Related]
14. Biomarkers and early detection of late onset anthracycline-induced cardiotoxicity in children.
Sherief LM; Kamal AG; Khalek EA; Kamal NM; Soliman AA; Esh AM
Hematology; 2012 May; 17(3):151-6. PubMed ID: 22664114
[TBL] [Abstract][Full Text] [Related]
15. Long-term cardiac effects of treatment for childhood leukemia.
Urbanova D; Urban L; Simkova I; Danova K; Mikuskova E; Mladosievicova B
Neoplasma; 2010; 57(2):179-83. PubMed ID: 20099983
[TBL] [Abstract][Full Text] [Related]
16. Correlation to NT-ProBNP and remodeling after cardiac surgery.
Boer BP; Vieira ML; Sampaio RO; Abensur H; Oliveira AG; Fernandes JR; Grinberg M
Arq Bras Cardiol; 2013 May; 100(5):469-75. PubMed ID: 23579620
[TBL] [Abstract][Full Text] [Related]
17. Tissue Doppler velocities of mitral annulus and NT-proBNP in patients with heart failure.
Tretjak M; Verovnik F; Benko D; Kozelj M
Eur J Heart Fail; 2005 Jun; 7(4):520-4. PubMed ID: 15921789
[TBL] [Abstract][Full Text] [Related]
18. Assessment of anthracycline-induced cardiotoxicity with biochemical markers.
Horacek JM; Pudil R; Jebavy L; Tichy M; Zak P; Maly J
Exp Oncol; 2007 Dec; 29(4):309-13. PubMed ID: 18199989
[TBL] [Abstract][Full Text] [Related]
19. N-terminal pro brain natriuretic peptide and cardiac function in doxorubicin administered pediatric patients.
Hongkan W; Soongswang J; Veerakul G; Sanpakit K; Punlee K; Rochanasiri W; Udompunturak S
J Med Assoc Thai; 2009 Nov; 92(11):1450-7. PubMed ID: 19938736
[TBL] [Abstract][Full Text] [Related]
20. Plasma N-terminal pro-brain natriuretic peptide: a marker of left ventricular hypertrophy in hypertrophic cardiomyopathy.
Brito D; Matias JS; Sargento L; Cabral MJ; Madeira HC
Rev Port Cardiol; 2004 Dec; 23(12):1557-82. PubMed ID: 15732658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
